RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
FDA approval for RAPIBLYK® (landiolol) for use in pediatric patients with SVT provides first therapeutic option for these ...
Most patients and doctors know that stress exacerbates AD. A new study pinpoints a neural mechanism that may be involved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results